Novel food: Nicotinamide riboside chloride
- Novel/traditional foods
Summary
The European Commission has extended the permitted use of the novel food nicotinamide riboside chloride to foods for special medical purposes and total diet replacement for weight control.
EU extends use of the novel food nicotinamide riboside chloride to foods for special medical purposes and meal replacements
Commission Implementing Regulation (EU) 2022/1160 of 5 July 2022 amending Implementing Regulation (EU) 2017/2470 as regards the conditions of use and the specifications of the novel food nicotinamide riboside chloride
Update
The European Commission has extended the permitted use of the novel food nicotinamide riboside chloride to foods for special medical purposes and total diet replacement for weight control.
What is changing?
The Commission has authorised and set out conditions for use of nicotinamide riboside chloride in foods for special medical purposes and meal replacements. These conditions, including maximum levels and additional specific labelling requirements, are set out in the Annex to the Regulation.
Why?
Following an application for extension of the use of nicotinamide riboside chloride to foods for special medical purposes and meal replacements, EFSA delivered a favourable opinion regarding its safety and bio-availability when added to such foods (EFSA 2021).
Timeline
The Regulation entered into force on 25 July 2022.
What are the major implications for exporting countries?
Producers of foods for special medical purposes and meal replacements may use nicotinamide riboside chloride as a source of niacin, in accordance with the specific conditions set out in the Regulation.
Background
Nicotinamide riboside chloride was authorised for use in food supplements for the adult population, excluding pregnant and lactating women, on the EU market by Commission Implementing Regulation (EU) 2020/16.
Resources
EFSA (2021) Scientific opinion on extension of use of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal, 19(11): 6843.
Sources
Commission Implementing Regulation (EU) 2022/1160
Disclaimer: Under no circumstances shall COLEAD be liable for any loss, damage, liability or expense incurred or suffered that is claimed to have resulted from the use of information available on this website or any link to external sites. The use of the website is at the user’s sole risk and responsibility. This information platform was created and maintained with the financial support of the European Union. Its contents do not, however, reflect the views of the European Union.